Breaking: Moderna’s mRNA Flu Vaccine Gets Unanimous Thumbs-Up Despite Risks, Low Efficacy
Read with caution - this story is only being covered by one news source that has a ‘low factuality’ rating, which means the outlet has a history of poor reporting practices. Learn more about factuality ratings here.2 Articles
2 Articles
Breaking: Moderna’s mRNA Flu Vaccine Gets Unanimous Thumbs-Up Despite Risks, Low Efficacy
The FDA’s Vaccines and Related Biological Products Advisory Committee today voted 9-0 to recommend approval of Moderna’s mRNA flu vaccine for the 50-64 and 65-plus age groups. Karl Jablonowski, Ph.D., senior research scientist for Children’s Health Defense, said, “The unanimous vote guarantees a lot of really good questions of harm will have to be answered in the post-marketing period, when that harm manifests in the population.” A federal advis…
A Better Flu Vaccine
by Gertrud U. Rey On June 18, 2026, the top advisory committee for the Food and Drug Administration (FDA) unanimously recommended Moderna’s new mRNA influenza vaccine, mRNA‑1010 (mFlusiva), for adults aged 50 and older. The vote marked the committee’s first review of a new vaccine application since 2023 and demonstrated strong support ahead of a … A Better Flu Vaccine Read More »
Coverage Details
Bias Distribution
- 100% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
